Wolf-Henning Boehncke, Friedrich Markus, Mrowietz Ulrich, Reich Kristian, Rosenbach Thomas, Sticherling Michael, Thaçi Diamant
Zentrum der Dermatologie und Venerologie, Johann-Wolfgang-Goethe-Universität, Frankfurt am Main.
J Dtsch Dermatol Ges. 2003 Aug;1(8):620-8. doi: 10.1046/j.1610-0387.2003.03014.x.
About 20% of all psoriasis patients require photo- and/or systemic therapy because of the severity of their disease. Side effects, contraindications, insufficient clinical responses, and lack of long-term efficacy underline the need for novel and improved anti-psoriatic therapies. In recent years, the technology has been established to generate therapeutic molecules from living cells capable of inhibiting disease-relevant mediators or cell-cell interactions. Several of these so-called biologics interfering with key steps in the immunopathogenesis of psoriasis have the potential to meet this need with regard to treating moderate to severe psoriasis. Here, the Psoriasis Study Group of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) analyses the established anti-psoriatic treatment modalities. With the shortcomings of these options in mind, biologics with an immediate relevance for clinical application in the treatment of psoriasis are discussed. The focus is on their potential medical advantages along with safety aspects. Moreover, legal and economical aspects with an impact on the use of biologics are addressed.
约20%的银屑病患者因病情严重需要光疗和/或全身治疗。副作用、禁忌症、临床反应不足以及缺乏长期疗效凸显了对新型和改进的抗银屑病疗法的需求。近年来，已建立了从能够抑制疾病相关介质或细胞间相互作用的活细胞中生成治疗分子的技术。其中几种所谓的生物制剂干扰银屑病免疫发病机制的关键步骤，在治疗中度至重度银屑病方面有潜力满足这一需求。在此，德国皮肤病研究协作组（ADF）的银屑病研究小组分析了已确立的抗银屑病治疗方式。考虑到这些治疗方案的缺点，讨论了对银屑病临床应用具有直接相关性的生物制剂。重点是它们潜在的医学优势以及安全性方面。此外，还探讨了影响生物制剂使用的法律和经济方面。
